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We evaluated the in situ expression of adhesion molecules
(E-selectin and vascular cell-adhesion molecule) and pro-
inflammatory/fibrogenic cytokines (IL-1b, TNF-a, TGF-
b1, and PDGF) in sections of normal skin, hypertrophic
scar, and hypertrophic scar previously treated with an
irradiated mixture of collagen-polyvinylpyrrolidone and
completely resolved. Expression of these proteins was
detected by indirect immunoperoxidase staining. The
hypertrophic scar group displayed an increased amount
of IL-1b, TNF-a, TGF-b1, and PDGF compared with
the normal skin and treated scar groups. Values were
statistically significant when cytokines in hypertrophic
scar and hypertrophic treated sections were compared.
Surprisingly, no differences were detected between nor-
mal skin and treated scars. On the other hand, differences
in levels of E-selectin and vascular cell-adhesion molecule
were not statistically significant between the groups,
Fibrosis is the pathologic frame of many common disorders,such as cirrhosis, chronic glomerulonephritis, lung fibrosis,post-surgery peritoneal adhesions, vascular restenosis, anddermal fibrosis, including scleroderma or hypertrophic andkeloid scars. In affected tissues, inflammation precedes
fibrosis with a dramatic increase in the expression of adhesion molecules.
The concomitant and excessive synthesis of soluble mediators from
inflammatory cells, such as fibrogenic cytokines, induces a loss of
balance, involving extracellular matrix (ECM) turnover disregulation
(Kovacs, 1991). Levels of pro-inflammatory and fibrogenic cytokines
are high in response to tissue damage, consistent with a chronic
inflammatory state that involves fibroblasts, keratinocytes, macrophages,
and T lymphocytes. These mediators, in turn, increase cytokine
receptors, proliferation, chemotaxis, and synthesis of ECM components.
IL-1, TNF-α, PDGF, and TGF-β isoforms actively participate in the
wound healing process (Gailit and Clark, 1994). They also show
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except for vascular cell-adhesion molecule, which
decreased in treated scars. Also, supernatants from
fibroblast cultures derived from treated hypertrophic scar,
showed a reduction in TGF-b1 and PDGF expression,
although apparently collagen synthesis was not affected.
Based on previous data from clinical studies in human
dermal fibrosis remodeling, and the results presented
here, we suggest that collagen-polyvinylpyrrolidone
modulates extracellular matrix turnover, mainly of colla-
gen, because expression levels of IL-1b, TNF-a, TGF-
b1, and PDGF were diminished. We infer that collagen-
polyvinylpyrrolidone participation could also modify the
inflammatory process observed in hypertrophic scarring,
by diminishing the expression of adhesion molecules,
as a consequence of lower levels of proinflammatory
cytokines, mainly IL-1b and TNF-a. Key words: fibrosis/
inflammation/therapy. J Invest Dermatol 111:828–834, 1998
persistent expression in hypertrophic and keloid scars (Ghahary et al,
1995), as does the intercellular adhesion molecule ICAM-1 (Castagnoli
et al, 1994), possibly in response to an irritation of the wound, to an
extensive area of damaged tissue [hypertrophic scar (HSc)] or to genetic
factors associated with local fibroblasts (keloid) (McPherson and Piez,
1988; Rockwell et al, 1989).
Reparative process research has focused on resolving HSc satisfactor-
ily, on increasing the rate and quality of wound healing, and on
avoiding fibrosis formation. In order to relieve these pathologic scars,
investigators have developed therapeutic strategies, including: physical
therapies, such as radiation, surgery, and pressure; chemical therapies,
such as corrosive acids and fixing solutions (formaline); and pharmaco-
logic therapies, such as corticosteroid administration (Darzi and
Chowdri, 1992; Soderberg et al, 1982; Ahn et al, 1991; Lawrence,
1991; Tang, 1992). The latter diminishes fibrosis associated with
recurrent inflammation by blocking adhesion molecule expression
(Chapman and Haskard, 1995), but with the drawback that these
immunosuppressors cannot be used for long periods and there is
recidivism of scarring. Other therapeutic approaches have tried to
block collagen biosynthesis (Rosenbloom et al, 1986; Kawaguchi et al,
1992a, b), but these compounds lack specificity and can therefore
affect the metabolism of normal tissues.
Our group has been working with a biologic drug named Fibroquel,
which is made of a γ-irradiated mixture of pepsinized porcine type I
collagen and polyvinylpyrrolidone (collagen-PVP). The compound has
shown beneficial effects when administered to wounds and rat fractures
(Almaza´n Dı´az et al, 1996), and to local fibrotic disorders, such as
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Table I. Clinical parameters of HSc treated with collagen-PVP
After treatmentb
Scar Number of
Patient Age (y) Sex Injured area(s) evolution (y) injectionsa pain erythema softness flattening
1 8 M Abdomen 4 3 – – 1/– 1/–
2 7 M Neck & chin 2 4 – – 1/– –
3 8 F Thorax 2 6 – – 1 1/–
4 16 F Neck, chin, & thorax 4 6 – – 1 1
5 20 M Thorax 0.5 6 – – 1 1
6 25 M Shoulder 3 6 – – 1 1
7 29 F Thigh 0.5 6 – 1/– 1 1/–
8 29 M Hand 0.7 6 – – 1 1/–
9 43 F Popliteal space 2 10 – – 1 1
aCollagen-PVP was administered once per week.
b–, absence; 1/–, moderate; 1, positive.
tendon and dermal fibrosis, where symptoms and volume diminished
and the inflammatory infiltrate disappeared in collagen-PVP treated
scars, with tissue architecture resembling normal skin.2 In vitro, collagen-
PVP increases collagen synthesis and diminishes the collagenolytic
activity of murine fibroblasts, whereas the collagenolytic activity of
murine macrophages is increased. These effects are unique and attribut-
able to the compound, because its components (collagen and polyvinyl-
pyrrolidone) do not have the same effect alone when compared with
collagen-PVP (Kro¨tzsch-Go´mez FE and Dı´az de Leo´n L, manuscript
in preparation). For this reason, we infer that the mechanism of action
of collagen-PVP is not a negative feedback, as reported when fibroblasts
are treated with collagen gels (Eckes et al, 1993).
In this study, the mechanism of action of collagen-PVP was
investigated by evaluating cytokine and adhesion molecule expression
in HSc. Also, we report the behavior of cultures of fibroblasts derived
from the same tissues by the analysis of collagen turnover and cytokine
expression.
MATERIALS AND METHODS
Tissue specimens Samples of human tissue were excised during plastic
surgery operation. Three were normal skin biopsies, four were HSc with a
disease duration of 4.3 6 1.5 y, and five were HSc with a disease duration of
3.1 6 1.4 y, previously treated with an intralesional administration of 0.2 ml
per week of collagen-PVP if scar length was 5 cm or less, 0.4 ml per week if
scar length was between 5 and 10 cm, and 0.6 ml per week if scar length was
10 cm or more, until normalization of the scar by clinical criteria (between 1
and 3 mo). A section of the samples was snap-frozen in liquid nitrogen.
Then they were cut at 4–6 µm and serial sections were mounted on γ-
methacryloxypropyltrimethoxisilane (Sigma, St. Louis, MO) coated slides.
Finally, sections were fixed in acetone at –20°C.
Histology and immunohistochemistry Herovici staining was performed
according to Herovici (1963). Immunohistochemical procedures were assessed
by blocking with 3% egg albumin (Sigma), except for the TGF-β1 assay in
which the blockade was done with 3% bovine albumin (Sigma), and then the
sections were incubated with a mouse anti-human E-selectin (ELAM-1) or
vascular cell-adhesion molecule (VCAM-1) monoclonal IgG at 25 µg (Genzyme,
Cambridge, MA) per ml, or a goat anti-human IL-1β, TNF-α, or PDGF
polyclonal IgG at 20 µg (R&D Systems, Minneapolis, MN) per ml. Anti-
PDGF antibodies recognize all isoforms (AA, AB, and BB). A chicken anti-
human TGF-β polyclonal IgG neutralizing antibody (R&D Systems), which
recognizes only isoforms 1 and 1.2 and has 100 times less affinity for TGF-β2,
was used at 20 µg per ml. Antibodies were incubated for 60 min at room
temperature. Binding was detected by incubating sections for 60 min at room
temperature with rabbit anti-mouse biotinylated IgG diluted 1:20 (Sigma) for
the adhesion molecules assay, with rabbit anti-goat biotinylated IgG, diluted
1:100 (Sigma) for IL-1, TNF-α, and PDGF detection or with rabbit anti-
chicken biotinylated IgG, diluted 1:750 (Pierce, Rockford, IL) for the TGF-β
assay. Avidin-peroxidase complex (Sigma) was used at a 1:20 dilution for
45 min at room temperature. The sections were developed in a solution of
diaminobenzidine, and counterstained with hematoxylin. Finally, sections were
2Dı´az de Leo´n HL, Kro¨tzsch-Go´mez FE, Guerrero-Padilla E, Cervantes-
Viramontes R, Reyes-Ma´rquez R: A novel approach for the treatment of
tissular fibrosis. Matrix Biol 145:401, 1994 (abstr.)
dehydrated with alcohol and xylene, and mounted in resin. Negative control
staining was performed with normal human serum diluted 1:100, instead of
primary antibody. At least two different sections were examined for each
patient. Adhesion molecule and cytokine expression was assessed by estimating
positively staining cells in blood vessels and cells spreading along one field
below the epidermis (see Results), and it was reported as the percentage of
immunoreactive cells; results were expressed as the mean 6 SEM. Associations
between quantifiable variables were determined using Student’s t test and
Mann–Whitney U test.
Fibroblast culture conditions Fibroblast cultures were established by frac-
tionating with scissors one fragment of normal skin, HSc, or HSc treated with
collagen-PVP and incubating the fragments with 0.1% bacterial collagenase
type II (Sigma) for 1 h at 37°C. The homogenate was centrifuged at 1250 rpm
for 2 min. The supernatant was eliminated and the pellet was resuspended in
Dulbecco’s modified Eagle medium (DMEM) high in glucose, supplemented
with heat-inactivated 10% fetal calf serum, 2 mM L-glutamine, and antibiotics
(100 U penicillin per ml and 5 µg streptomycin per ml). Cells were grown at
37°C in 5% CO2 in air. Cells between passages 3 and 4 were used for the
experiments. Every experimental condition was normalized by DNA content
and tested at least in triplicate, except for the cytokine assay, which was tested
in duplicate.
Collagen synthesis The assay was achieved by seeding 105 fibroblasts from
normal skin, HSc, or HSc previously treated with collagen-PVP, in 0.5 ml
DMEM with 10% fetal calf serum, 2 mM L-glutamine, and 50 µg ascorbate
per ml in 24 well plates, incubating them for 48 h at 37°C in 5% CO2 in air.
Then the medium was eliminated and the cultures were incubated for 3 h at
37°C in 5% CO2 in air, in DMEM without fetal calf serum, and with 2 mM
L-glutamine and 50 µg ascorbate per ml. The medium was replaced with the
same fresh medium supplemented with 0.5 µCi per ml of L-[U-14C]proline 50
µCi per ml (Amersham, U.K.) (Dieggelmann et al, 1990). Collagenous and
noncollagenous protein synthesis were evaluated in homogenized monolayer
and supernatant fractions, and collagen content was calculated according to the
Peterkofsky and Dieggelmann formula (Peterkofsky and Dieggelmann, 1971).
Cytokine expression IL-1β, TNF-α, TGF-β1, and PDGF-AB were deter-
mined in supernatants of cultures under the conditions mentioned above. Two
hundred microliters were assayed by enzyme-linked immunosorbent assay
according to the manufacturer’s instructions (R&D Systems).
RESULTS
Clinical observations Features of a group of nine patients with
HSc were evaluated. After a mean treatment period of 8 wk with
collagen-PVP, as mentioned in Materials and Methods, the scars got soft
and were flattened until reaching normal skin border (Table I; Fig 1).
It is important to note that none of the patients presented relapse of
hypertrophy after 2.5 y.
Herovici staining Sections of normal skin, HSc, and HSc previously
treated with collagen-PVP and clinically resolved were stained following
the Herovici procedure. HSc were quite different from normal skin
(Fig 2a, b); the epidermal profile was flattened, whereas in normal
skin it was irregular with rete ridges. In scar sections, type I collagen
fibers (red in Fig 2b) were present with parallel distributions in papillary
dermis with respect to epidermis and in nodular zones all along the
deep dermis (Fig 2b, small arrow), and type III collagen (blue fibers)
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Figure 1. HSc before and after treatment with collagen-PVP. Forty-
three year old female patient with HSc in the popliteal space with 2 y of
evolution (a). The scar was treated for 10 wk with a weekly intralesional
administration of 0.4 ml in the collagen-PVP. Note the mark of the scar is
present, although the skin border has been reached, also erythema is absent and
the patient reported no pain after the first 3 wk of treatment (b).
Figure 2. Collagen-PVP effect on tissue architecture restoration.
Photomicrographs of human skin and scar tissue with or without treatment,
stained with Herovici technique. (a) Normal skin exhibiting rete ridges, reticular
type I collagen fibers in red, type III collagen fibers in blue in papillary
dermis. (b) HSc without rete ridges, type I collagen distributed in whorl-like
arrangements and nodular areas (small arrow). (c) HSc treated with collagen-PVP
resembles normal skin, with type III collagen present in papillary dermis (big
arrow) and showing a hair follicle (small arrow). Scale bar: 1000 µm.
below the epidermis was reduced. On the other hand, type I collagen
distribution in normal skin was characteristically reticular, and type III
collagen was more abundant in the papillary dermis than in the HSc
sections. Interestingly, collagen-PVP-treated HSc (Fig 2c) showed a
type I collagen distribution and a type III collagen zone (big arrow)
similar to those observed in normal skin, and in some cases partial
recovering of rete ridges and the presence of cutaneous appendages
were observed (Fig 2c, small arrow).
In situ expression of proinflammatory and fibrogenic
cytokines IL-1β, TNF-α, TGF-β1, and PDGF showed strong
differences among the groups (Figs 3–6). HSc sections [part (c) in each
montage] revealed more cells expressing these mediators than either
normal skin or collagen-PVP treated HSc [parts (b) and (d), respectively,
in each montage] (IL-1β, p 5 0.036; TNF-α, p 5 0.036; and PDGF,
p 5 0.003, treated versus untreated HSc) (Fig 7a). On the other hand,
blood vessels also exhibited the same pattern as spread cells (IL-1β,
p 5 0.002; TNF-α, p , 0.001; and PDGF, p 5 0.01, treated versus
untreated HSc) (Fig 7b). In both cases, endothelium and spread cells
in treated scars had cytokine levels similar to or lower than those of
normal skin, although these differences were not statistically significant.
Immunoreactivity of tested cytokines (large arrows) was consistently
Figure 3. Immunolocalization of IL-1b in human skin sections frozen
with the immunoperoxidase technique (avidin-biotin-peroxidase
system). (a) Photomicrograph of negative control; (b) photomicrograph of
normal skin; (c) photomicrograph of HSc, arrows indicate immunoreactive cells;
(d) photomicrograph of HSc treated with collagen-PVP. Scale bar: 200 µm.
localized in the papillary dermis, where typical HSc nodules of fibrosis
were absent, except for TGF-β1, which was more widely spread.
The stratum basalic of the epidermis also showed reactivity; however,
negative controls (Fig 4a, small arrow) were also positive in the basal
layers of the epidermis. We attribute these differences to the intensity
of skin pigmentation. This artifact did not exclude the possibility of
epidermal reactivity, but obscured a quantitative interpretation, because
keratinocytes are important producers of several cytokines (Streilein,
1993).
In situ expression of adhesion molecules ELAM-1 and VCAM-
1 were detected in normal skin and HSc (Figs 8b, c, 9b, c, respectively).
In scars previously treated with collagen-PVP (Figs 8d, 9d), both
molecules showed slightly lower levels when compared with normal
skin and HSc groups, but only the difference of VCAM-1 levels
between normal skin and treated HSc were statistically significant
(IL-1β, p 5 0.036). In contrast, levels of expression of ELAM-1
were different, although not statistically significant among the groups
(Fig 10). Even when we only quantitated the percentage of immuno-
staining in endothelium, other sites also showed reactivity, such as
interstitial inflammatory infiltrated cells and some isolated labels, maybe
due to soluble ELAM-1.
Fibroblast culture findings There was no difference in collagen
synthesis among the different cultures assessed (Fig 11a); however,
there were differences in cytokine expression in the supernatants of
fibroblast cultures derived from normal skin, HSc, and treated HSc
(Fig 11b), where only TGF-β1 and PDGF-AB were quantifiable,
because IL-1β and TNF-α were not detected by our enzyme-linked
immunosorbent assay systems. TGF-β1 was 3.5-fold higher in normal
skin as well as in HSc when compared with treated HSc fibroblasts,
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Figure 4. Immunolocalization of TNF-a in human skin sections frozen
with the immunoperoxidase technique (avidin-biotin-peroxidase
system). (a) Photomicrograph of negative control; (b) photomicrograph of
normal skin; (c) photomicrograph of HSc, arrows indicate immunoreactive cells;
(d) photomicrograph of HSc treated with collagen-PVP. Scale bar: 200 µm.
whereas PDGF-AB levels were similar between normal skin and treated
HSc fibroblasts, and they were 1-fold higher in HSc.
DISCUSSION
In this study we found that fibrogenic/proinflammatory cytokines were
predominantly detected in the upper dermis of normal skin (Figs 3,
4, 6), except for TGF-β1 (Fig 5), which was also found in the deep
dermis in nodular zones, as previously described (Ghahary et al, 1995).
HSc manifested a strong parallel increase of all cytokines measured in
spread cells, as well as in blood vessels (Fig 7). Some of these data
contrast with those of Castagnoli et al (1993), which indicate similar
levels of TNF-α in HSc and normal skin.
TGF-β is synthesized by many cells and tissues, including normal
skin and HSc (Ghahary et al, 1995). Its localization in fibroblast-like
cells derived from fibrotic pathologies like hypertrophic scarring, as
well as in endothelial cells adjacent to mononuclear cells, suggests a
relationship between factor-producing cells and those responsible for
collagen overexpression, where the connection could be either autoc-
rine or paracrine (Zhang et al, 1995). Furthermore, TGF-β participates
with PDGF in an orchestrated way. Here we have shown that TGF-
β1, as well as PDGF-AB, were diminished in fibroblast cultures derived
from treated HSc when they were compared with normal skin and
HSc fibroblasts (Fig 11b). This is important, because generally fibroblasts
are considered to be effector cells regulated by inflammatory cells.
These results could indicate that the fibroblast itself has an ability for
autoregulation, perhaps through collagen-PVP modulation. Because
collagen synthesis by fibroblasts did not show variations among the
different cultures tested (Fig 11a), the results suggest that collagen
synthesis is not regulated in an autocrine fashion, at least by TGF-β1
and/or PDGF-AB. Therefore, it is necessary to evaluate collagen
Figure 5. Immunolocalization of TGF-b1 in human skin sections
frozen with the immunoperoxidase technique (avidin-biotin-peroxidase
system). (a) Photomicrograph of negative control; (b) photomicrograph of
normal skin; (c) photomicrograph of HSc, arrows indicate immunoreactive cells;
(d) photomicrograph of HSc treated with collagen-PVP. Scale bar: 200 µm.
turnover in this lineage, as well as the cooperative effects between
inflammatory cells and fibroblasts.
IL-1 and TNF-α have similar fibrogenic activities. These two
cytokines participate in ECM turnover and inflammation, their principal
source being leukocytes; however, they have also been detected in
mesenchymal cells and epidermis as a significant reservoir. Nevertheless,
we were unable to detect these cytokines in fibroblast cultures.
Here we report that in collagen-PVP-treated HSc, completely
resolved by clinical criteria, all the tested cytokines (IL-1β, TNF-α,
TGF-β1, PDGF) analyzed by immunohistochemistry showed dimin-
ished expression, even below normal levels, and a similar reduction in
the expression of adhesion molecules was observed (Fig 10). This
suggests a correlation between them, although only VCAM-1 was
statistically significant when normal skin versus treated HSc were
compared. Because collagen-PVP treatment has been shown to modify
human dermal fibrosis, as presented here (Table I), we infer that its
mechanism of action can be directly associated with the inflammatory
process observed in HSc, possibly by the decrease in the expression of
adhesion molecules, which are upregulated in response to proinflam-
matory cytokines, IL-1β, and TNF-α. Also, low levels of these
cytokines observed in endothelium from treated HSc could downregul-
ate chemotaxis. Therefore, we suggest that the chronic inflammatory
process is interrupted by collagen-PVP action, diminishing the partial
production of fibrogenic soluble factors, including their self-expression
by spreading cells, probably connective tissue cells and inflammatory
infiltrates. This mechanism allows the recovery of tissue homeostasis,
although it leads to gradual elimination of fibrosis by the increased
turnover of ECM components. This is because ECM metabolism is
regulated by various mechanisms, including soluble factors or cytokines
(Postlethwaite et al, 1988; Gailit and Clark, 1994), as well as the ECM
itself (Massague´, 1990). It could be possible that the collagen-PVP
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Figure 6. Immunolocalization of PDGF in human skin sections frozen
with the immunoperoxidase technique (avidin-biotin-peroxidase
system). (a) Photomicrograph of negative control; (b) photomicrograph of
normal skin; (c) photomicrograph of HSc, arrows indicate immunoreactive cells;
(d) photomicrograph of HSc treated with collagen-PVP. Scale bar: 200 µm.
Figure 7. Collagen-PVP effect on pro-inflammatory cytokine expression
in HSc. The percentage of cytokine expressing immunoreactive cells was
determined for normal skin, HSc, and collagen-PVP treated HSc. Cytokine
values were compared between treated and untreated samples as mentioned in
Materials and Methods. They were different in (a) spread cells (IL-1β, p 5 0.036;
TNF-α, p 5 0.036, and PDGF, p 5 0.003) and (b) blood vessels (IL-1β, p 5
0.002, TNF-α, p , 0.001 and PDGF, p 5 0.01, treated versus untreated HSc).
Results represent the mean 6 SEM of at least two sections of each tissue from
normal skin (n 5 3), HSc (n 5 4), and HSc previously treated with collagen-
PVP (n 5 5).
complex is recognized by cell receptors, such as integrins, and then
this modifies the intracellular signals for cytokine expression and/or
ECM and metalloproteases synthesis; however, it is necessary to perform
the appropriate experiments to explore these possibilities.
It is evident that these cytokines are associated with the persistence
of an inflammatory infiltrate, which generates new signals capable of
recruiting more leukocytes and which stimulates the expression of
Figure 8. Human skin sections frozen with the immunoperoxidase
technique (avidin-biotin-peroxidase system) using an anti-ELAM-1 as
primary antibody. (a) Photomicrograph of negative control; (b)
photomicrograph of normal skin; (c) photomicrograph of HSc, arrows indicate
immunoreactive cells; (d) photomicrograph of HSc treated with collagen-PVP.
Scale bar: 200 µm.
adhesion molecules. This could perpetuate the inflammatory process
present in hypertrophic scarring; however, we have found that collagen-
PVP is a good choice for treatment not only in dermal fibrosis, as has
been shown, but also in other fibrotic processes, such as fibrotic
Achilles tendon (unpublished results). Collagen-PVP has the advantage
of being a biologic drug with minimal risks, because no side-effects
have been detected in healthy volunteers and HSc patients treated for
long periods (even 14 y) with the drug. This was judged clinically and
by laboratory tests applied before and after treatment (data not shown).
Even though it is well known that nonhuman collagen implants are
capable of inducing heterologous anticollagen antibodies (Ellingsworth
et al, 1986; Trentham, 1986; Vanderveen et al, 1986; Hyder et al,
1992), no evidence exists to associate them with autoimmune diseases
related to collagen dermal implants (Singh and Fries, 1994; Lewy,
1994). Furthermore, little is known about porcine collagen implants,
as in the case of collagen-PVP. Generally, collagen implants consist of
insoluble fibrilar collagens resuspended in saline solutions, in such a
way that the structure of these implants is quite different from that
seen in collagen-PVP. Collagen association with polyvinylpyrrolidone,
and the cross-linking favored by γ-irradiation, confers on it various
physicochemical properties, such as the impossibility of forming a gel
when diluted in culture medium at 37°C and neutral pH (data not
shown); therefore, collagen-PVP does not behave like other collagen
implants. Moreover, electrophoretic analysis demonstrated a change in
the relative mobility of collagen-PVP when compared with the mixture
without γ-irradiation or the components alone (Chimal-Monroy
et al, 1997).
Based on the results obtained in this study, in particular the low
levels of fibrogenic cytokines and adhesion molecules in treated versus
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Figure 9. Human skin sections frozen with the immunoperoxidase
technique (avidin-biotin-peroxidase system) using an anti-VCAM-1 as
primary antibody. (a) Photomicrograph of negative control; (b)
photomicrograph of normal skin; (c) photomicrograph of HSc, arrows indicate
immunoreactive cells; (d) photomicrograph of HSc treated with collagen-PVP.
Scale bar: 200 µm.
Figure 10. Collagen-PVP effect on adhesion molecule expression in
treated HSc. The percentage of adhesion molecule-expressing immunoreactive
cells was determined in blood vessels of normal skin, HSc, and collagen-PVP-
treated HSc. Adhesion molecule values were compared between treated and
untreated samples as mentioned in Materials and Methods but they were not
different; however, when normal skin was compared with treated HSc, these
values were different with a statistical level of p 5 0.036 for VCAM-1. Results
represent the mean 6 SEM of at least two sections of each tissue from normal
skin (n 5 3), HSc (n 5 4), and HSc previously treated with collagen-PVP
(n 5 5).
Figure 11. Fibroblasts derived from HSc treated with collagen-PVP
were assayed for collagen synthesis and cytokine expression. The
percentage of relative collagen was determined by [14C]-Proline incorporation,
values were compared between treated and untreated groups, but they were
not significantly different. Results represent the mean 6 SD of triplicates of
each culture (a). TGF-β1 and PDGF-AB levels were evaluated by enzyme-
linked immunosorbent assay. Results represent the mean 6 SD of two different
experiments performed by duplicate. Where p values for TGF-β1 are ø0.05
for normal skin or HSc versus HSc treated, and ø0.003 for PDGF-AB for
normal skin or HSc treated versus HSc (b), normal skin, HSc, and collagen-
PVP-treated HSc.
untreated HSc, we suggest that collagen-PVP can modulate extracellular
matrix turnover, mainly of collagen, and thus block the progression of
the fibrotic process.
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